BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Topatana W, Juengpanich S, Li S, Cao J, Hu J, Lee J, Suliyanto K, Ma D, Zhang B, Chen M, Cai X. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. J Hematol Oncol. 2020;13:118. [PMID: 32883316 DOI: 10.1186/s13045-020-00956-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 George RR, Thomas R, Davice A, Mathew MS. Veliparib for the treatment of solid malignancies. J Oncol Pharm Pract 2022;:10781552221073990. [PMID: 35037770 DOI: 10.1177/10781552221073990] [Reference Citation Analysis]
2 Elbanna M, Chowdhury NN, Rhome R, Fishel ML. Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy. Front Oncol 2021;11:749496. [PMID: 34733787 DOI: 10.3389/fonc.2021.749496] [Reference Citation Analysis]
3 Creeden JF, Nanavaty NS, Einloth KR, Gillman CE, Stanbery L, Hamouda DM, Dworkin L, Nemunaitis J. Homologous recombination proficiency in ovarian and breast cancer patients. BMC Cancer 2021;21:1154. [PMID: 34711195 DOI: 10.1186/s12885-021-08863-9] [Reference Citation Analysis]
4 Wang J, Zhang Q, Han J, Zhao Y, Zhao C, Yan B, Dai C, Wu L, Wen Y, Zhang Y, Leng D, Wang Z, Yang X, He S, Bo X. Computational methods, databases and tools for synthetic lethality prediction. Brief Bioinform 2022:bbac106. [PMID: 35352098 DOI: 10.1093/bib/bbac106] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Doultsinos D, Mills IG. Derivation and Application of Molecular Signatures to Prostate Cancer: Opportunities and Challenges. Cancers (Basel) 2021;13:495. [PMID: 33525365 DOI: 10.3390/cancers13030495] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
6 Stoczynska-Fidelus E, Węgierska M, Kierasińska A, Ciunowicz D, Rieske P. Role of Senescence in Tumorigenesis and Anticancer Therapy. J Oncol 2022;2022:5969536. [PMID: 35342397 DOI: 10.1155/2022/5969536] [Reference Citation Analysis]
7 Franzese O, Torino F, Giannetti E, Cioccoloni G, Aquino A, Faraoni I, Fuggetta MP, De Vecchis L, Giuliani A, Kaina B, Bonmassar E. Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment? Int J Mol Sci 2021;22:10672. [PMID: 34639014 DOI: 10.3390/ijms221910672] [Reference Citation Analysis]
8 Pansare K, Mohanty B, Dhotre R, Pettiwala AM, Parab S, Gupta N, Gera P, Gardi N, Dugge R, Sahu P, Alhans R, Kowtal P, Chaudhari P, Sarin R. Aspirin Inhibition of Group VI Phospholipase A2 Induces Synthetic Lethality in AAM Pathway Down-Regulated Gingivobuccal Squamous Carcinoma. Cells 2021;11:123. [PMID: 35011685 DOI: 10.3390/cells11010123] [Reference Citation Analysis]
9 Oxe KC, Larsen DH. Treacle is Upregulated in Cancer and Correlates With Poor Prognosis. Front Cell Dev Biol 2022;10:918544. [DOI: 10.3389/fcell.2022.918544] [Reference Citation Analysis]
10 Lokhande L, Kuci Emruli V, Eskelund CW, Kolstad A, Hutchings M, Räty R, Niemann CU, Grønbaek K, Jerkeman M, Ek S. Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma. Cancer Rep (Hoboken) 2021;:e1524. [PMID: 34319003 DOI: 10.1002/cnr2.1524] [Reference Citation Analysis]
11 Stefanou DT, Souliotis VL, Zakopoulou R, Liontos M, Bamias A. DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer? Biomedicines 2022;10:82. [DOI: 10.3390/biomedicines10010082] [Reference Citation Analysis]
12 Yang X, Gao L, Wang N, Li Y, Song L, He T, Zhang W, Yi C, He G, Wu Q, Gong C. A self-assembly reproducible nanoplatform enables cancer phenotypic lethality in solid tumors. Materials & Design 2022;214:110408. [DOI: 10.1016/j.matdes.2022.110408] [Reference Citation Analysis]
13 Cao JS, Lu ZY, Chen MY, Zhang B, Juengpanich S, Hu JH, Li SJ, Topatana W, Zhou XY, Feng X, Shen JL, Liu Y, Cai XJ. Artificial intelligence in gastroenterology and hepatology: Status and challenges. World J Gastroenterol 2021; 27(16): 1664-1690 [PMID: 33967550 DOI: 10.3748/wjg.v27.i16.1664] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Du R, Sullivan DK, Azizian NG, Liu Y, Li Y. Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells. BMC Cancer 2021;21:237. [PMID: 33676427 DOI: 10.1186/s12885-021-07967-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Gundogdu R, Erdogan MK, Ditsiou A, Spanswick V, Garcia-Gomez JJ, Hartley JA, Esashi F, Hergovich A, Gomez V. hMOB2 deficiency impairs homologous recombination-mediated DNA repair and sensitises cancer cells to PARP inhibitors. Cell Signal 2021;87:110106. [PMID: 34363951 DOI: 10.1016/j.cellsig.2021.110106] [Reference Citation Analysis]
16 Karagiannakos A, Adamaki M, Tsintarakis A, Vojtesek B, Fåhraeus R, Zoumpourlis V, Karakostis K. Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. Cancers 2022;14:664. [DOI: 10.3390/cancers14030664] [Reference Citation Analysis]
17 Luxenburger A, Bougen-Zhukov N, Fraser MG, Beetham H, Harris LD, Schmidt D, Cameron SA, Guilford PJ, Evans GB. Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer. J Med Chem 2021;64:18114-42. [PMID: 34878770 DOI: 10.1021/acs.jmedchem.1c01609] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kciuk M, Gielecińska A, Mujwar S, Mojzych M, Kontek R. Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response. Int J Mol Sci 2022;23:3555. [PMID: 35408915 DOI: 10.3390/ijms23073555] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Stoof J, Harrold E, Mariottino S, Lowery MA, Walsh N. DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. Front Cell Dev Biol 2021;9:749490. [PMID: 34712667 DOI: 10.3389/fcell.2021.749490] [Reference Citation Analysis]
20 Pei H, Guo W, Peng Y, Xiong H, Chen Y. Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective. Med Res Rev 2022. [PMID: 35312190 DOI: 10.1002/med.21886] [Reference Citation Analysis]
21 Tang YH, Lin CY, Lai CH. Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers. Genes (Basel) 2021;12:1593. [PMID: 34680987 DOI: 10.3390/genes12101593] [Reference Citation Analysis]
22 Chan KK, Abdul-Sater Z, Sheth A, Mitchell DK, Sharma R, Edwards DM, He Y, Nalepa G, Rhodes SD, Clapp DW, Sierra Potchanant EA. SIK2 kinase synthetic lethality is driven by spindle assembly defects in FANCA-deficient cells. Mol Oncol 2021. [PMID: 34058059 DOI: 10.1002/1878-0261.13027] [Reference Citation Analysis]
23 Kciuk M, Gielecińska A, Mujwar S, Mojzych M, Marciniak B, Drozda R, Kontek R. Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies. J Enzyme Inhib Med Chem 2022;37:1278-98. [PMID: 35506234 DOI: 10.1080/14756366.2022.2052868] [Reference Citation Analysis]
24 Akimov Y, Aittokallio T. Re-defining synthetic lethality by phenotypic profiling for precision oncology. Cell Chem Biol 2021;28:246-56. [PMID: 33631125 DOI: 10.1016/j.chembiol.2021.01.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Shah S, Rachmat R, Enyioma S, Ghose A, Revythis A, Boussios S. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations. Int J Mol Sci 2021;22:12628. [PMID: 34884434 DOI: 10.3390/ijms222312628] [Reference Citation Analysis]
26 Meng X, Gao JZ, Gomendoza SMT, Li JW, Yang S. Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations. Front Med (Lausanne) 2021;8:737951. [PMID: 34671620 DOI: 10.3389/fmed.2021.737951] [Reference Citation Analysis]
27 Molinaro C, Martoriati A, Cailliau K. Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies. Cancers (Basel) 2021;13:3819. [PMID: 34359720 DOI: 10.3390/cancers13153819] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Wang CY, Chao CH. p53-Mediated Indirect Regulation on Cellular Metabolism: From the Mechanism of Pathogenesis to the Development of Cancer Therapeutics. Front Oncol 2022;12:895112. [PMID: 35707366 DOI: 10.3389/fonc.2022.895112] [Reference Citation Analysis]
29 Everix L, Nair S, Driver CHS, Goethals I, Sathekge MM, Ebenhan T, Vandevoorde C, Bolcaen J. Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma. Cancers (Basel) 2022;14:1821. [PMID: 35406593 DOI: 10.3390/cancers14071821] [Reference Citation Analysis]
30 Goff PH, Bhakuni R, Pulliam T, Lee JH, Hall ET, Nghiem P. Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer? Cancers (Basel) 2021;13:3415. [PMID: 34298632 DOI: 10.3390/cancers13143415] [Reference Citation Analysis]
31 Meng M, Zhong K, Jiang T, Liu Z, Kwan HY, Su T. The current understanding on the impact of KRAS on colorectal cancer. Biomed Pharmacother 2021;140:111717. [PMID: 34044280 DOI: 10.1016/j.biopha.2021.111717] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Gönül Geyik Ö, Anichini G, Ulukaya E, Marra F, Raggi C. DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. Cells 2022;11:1463. [DOI: 10.3390/cells11091463] [Reference Citation Analysis]